Iprivask Dosage

Generic name: desirudin
Dosage form: subcutaneous injection

This dosage information does not include all the information needed to use Iprivask safely and effectively. See full prescribing information for Iprivask.

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

DOSAGE AND ADMINISTRATION

All patients should be evaluated for bleeding disorder risk before prophylactic administration of Iprivask (see PRECAUTIONS, Drug Interactions).Initial Dosage: In patients undergoing hip replacement surgery, the recommended dose of Iprivask is 15 mg every 12 hours administered by subcutaneous injection with the initial dose given up to 5 to 15 minutes prior to surgery, but after induction of regional block anesthesia, if used (see WARNINGS, Spinal/Epidural Anesthesia). Up to 12 days administration (average duration 9 to 12 days) of Iprivask has been well tolerated in controlled clinical trials.

Degree of RenalInsufficiency CreatinineClearance[mL/min/1.73m2 bodysurface area] aPTT Monitoring and Dosing Instructions
Moderate greater than or equal to 31 to 60 Initiate therapy at 5 mg every 12 hours by subcutaneous injection.Monitor aPTT and serum creatinine at least daily. If aPTTexceeds 2 times control:1. Interrupt therapy until the value returns to less than 2 timescontrol.2. Resume therapy at a reduced dose guided by the initial degreeof aPTT abnormality
Severea less than 31 Initiate therapy at 1.7 mg every 12 hours by subcutaneousinjection. Monitor aPTT and serum creatinine at least daily. IfaPTT exceeds 2 times control:1. Interrupt therapy until the value returns to less than 2 timescontrol.2. Consider further dose reductions guided by the initial degreeof aPTT abnormality
Use in Renal Insufficiency See CLINICAL PHARMACOLOGY, Special Populations, Renal Insufficiency and WARNINGS, Renal Insufficiency. Use in Hepatic Insufficiency. In the absence of clinical studies in this population, dosing recommendations cannot be made at this time (see CLINICAL PHARMACOLOGY, Metabolism, Special Populations, Hepatic Insufficiency, and PRECAUTIONS, Hepatic Insufficiency).

Administration:
Directions on Preparation
Use Iprivask before the expiration date given on the carton and container.
1. Reconstitution should be carried out under sterile conditions.

2. Remove plastic flip-top cap from IprivaskVial. Remove back cover of Vial Adapter package. Attach Vial Adapter to Vial by using the outer package to handle Adapter. Push Adapter down onto Vial until spike pierces rubber stopper and snaps into place. Discard Vial Adapter package.

3. Remove Syringe cap by twisting and pulling gently. Attach Syringe to Adapter on Vial by twisting. Slowly push plunger down to completely transfer solution into Vial. Leaving Syringe connected to Vial, gently swirl. Round tablet in Vial will dissolve within 10 seconds.

4. With Syringe still connected to Vial, turn Vial upside down and withdraw entire contents of Vial back into Syringe. Remove Syringe from Vial and hold it with plunger-end down.

5. You must use enclosed Eclipse™ needle. Attach Needle to Syringe by twisting. Pull pink lever down and uncap needle. You are ready to inject Iprivask. After injection, flip up pink lever to cover needle until it snaps into place. Dispose of the used Syringe in a Sharps® container.

Iprivask should not be mixed with other injections, solvents, or infusions. Iprivask is administered by subcutaneous injection. It must not be administered by intramuscular injection. Subcutaneous Injection Technique: Select a syringe with a 26 or 27 gauge needle which is approximately ½ inch in length for administration of Iprivask.  Withdraw the entire reconstituted solution (15.75 mg desirudin/0.5 mL) into thesyringe and inject the total volume subcutaneously.

Patients should be sitting or lying down and Iprivask injection administered by deep subcutaneous injection. Administration should be alternated between the left and right anterolateral and left and right posterolateral thigh or abdominal wall. The whole length of the needle should be introduced into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. To minimize bruising, do not rub the injection site after completion of the injection.
Hide
(web3)